Successful use of gabapentin in acute pain management following burn injury: A case series

Pain Medicine

Volumn 9, Issue 3, 2008, Pages 371-376

  Gray, Paul ^a,b   Williams, Bronwyn ^b   Cramond, Tess ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Burn Injury; Gabapentin; Human; Neuropathic Pain; Pain Management

Indexed keywords

GABAPENTIN; IBUPROFEN; MORPHINE; OXYCODONE; PARACETAMOL;

ABSENCE OF SIDE EFFECTS; ADULT; ANALGESIA; ARTICLE; BURN; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEBRIDEMENT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HUMAN; MALE; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; SKIN TRANSPLANTATION;

ADULT; AMINES; ANALGESICS; BURNS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN;

EID: 41549153793     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00149.x     Document Type: Article

References (62)

1. Coderre TJ, Melzack R. Increased pain sensitivity following heat injury involves a central mechanism. Behav Brain Res 1985;15(3):259-62.
2. Coderre TJ, Melzack R. Central neural mediators of secondary hyperalgesia following heat injury in rats: Neuropeptides and excitatory amino acids. Neurosci Lett 1991;131(1):71-4.
3. Choinere M. The pain of burns. In: Wall P, Melzack R, eds. Textbook of Pain. Edinburgh: Churchill Livingstone; 1988:402-8.
4. Henry DB, Foster RL. Burn pain management in children. Pediatr Clin North Am 2000;47(3):681-98, ix -x.
5. Latarjet J, Choinere M. Pain in burn patients. Burns 1995;21(5):344-8.
6. Kowalske K, Tanelian D. Burn pain: Evaluation and management. Anesthesiol Clin North America 1997;15(2):269-83.
7. Silbert B, Osgood PF, Carr DB. Burn pain. In:
8. Biebuyck J, ed. Anaesthesia: Biological Foundations. Philadelphia, PA: Lippincott-Raven; 1997:759-73.
9. Gallagher G, Rae CP, Kinsella J. Treatment of pain in severe burns. Am J Clin Dermatol 2000;1(6):329-35.
10. Ulmer JF. Burn pain management: A guideline-based approach. J Burn Care Rehabil 1998;19(2):151-9.
11. Ashburn MA. Burn pain: The management of procedure-related pain. J Burn Care Rehabil 1995;16(3Pt2):365-71.
12. Malenfant A, Forget R, Papillon J, et al. Prevalence and characteristics of chronic sensory problems in burn patients. Pain 1996;67(2-3):493-500.
13. Dauber A, Osgood PF, Breslau A. Chronic persistent pain after severe burns: A survey of 358 burn survivors. Pain Med 2002;3:6-17.
14. Choiniere M, Melzack R, Papillon J. Pain and paresthesia in patients with healed burns: An exploratory study. J Pain Symptom Manage 1991;6(7):437-44.
15. Choiniere M, Melzack R, Rondeau J, Girard N, Paquin MJ. The pain of burns: Characteristics and correlates. J Trauma 1989;29(11):1531-9.
16. Altier N, Dion D, Boulanger A, Choiniere M. Successful use of methadone in the treatment of chronic neuropathic pain arising from burn injuries: A case-study. Burns 2001;27(7):771-5.
17. Jun JH, Yaksh TL. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 1998;86(2):348-54.
18. Nozaki-Taguchi N, Yaksh TL. A novel model of primary and secondary hyperalgesia after mild thermal injury in the rat. Neurosci Lett 1998;254:25-8.
19. Allen JW, Yaksh TL. Tissue injury models of persistent nociception in rats. Methods Mol Med 2004;99:25-34.
20. Nozaki-Taguchi N, Yaksh TL. Pharmacology of spinal glutamatergic receptors in post-thermal injury-evoked tactile allodynia and thermal hyperalgesia. Anesthesiology 2002;96(3):617-26.
21. Nozaki-Taguchi N, Yaksh TL. Spinal and peripheral mu opioids and the development of secondary tactile allodynia after thermal injury. Anesth Analg 2002;94(4):968-74.
22. Keinanen K, Wisden W, Sommer B, et al. A family of AMPA-selective glutamate receptors. Science 1990;249(4968):556-60.
23. Hollmann M, Hartley M, Heinemann S. Ca 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991;252(5007):851-3.
24. Engelman HS, Allen TB, MacDermott AB. The distribution of neurons expressing calcium-permeable AMPA receptors in the superficial laminae of the spinal cord dorsal horn. J Neurosci 1999;19(6):2081-9.
25. Sorkin LS, Yaksh TL, Doom CM. Mechanical allodynia in rats is blocked by a Ca 2+ permeable AMPA receptor antagonist. Neuroreport 1999;10(17):3523-6.
26. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res 1998;810(1-2):93-9.
27. Petersen KL, Rowbotham M. A new human experimental pain model: The heat/ capsaicin sensitization model. Neuroreport 1999;10:1511-6.
28. Pedersen JL, Kehlet H. Secondary hyperalgesia to heat stimuli after burn injury in man. Pain 1998;76(3):377-84.
29. Pedersen JL, Kehlet H. Hyperalgesia in a human model of acute inflammatory pain: A methodological study. Pain 1998;74(2-3):139-51.
30. Dirks J, Petersen KL, Rowbotham MC, Dahl JB. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 2002;97(1):102-7.
31. Jonsson A, Cassuto J, Hanson B. Inhibition of burn pain by intravenous lignocaine infusion. Lancet 1991;338:151-2.
32. Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62(2):218-25.
33. Konig SA, Schenk M, Sick C, et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: Review of valproate hepatotoxicity in adults. Epilepsia 1999;40(7):1036-40.
34. Pohlmann Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003;108(2):142-5.
35. Kumbhat S, Meyer N, Schurr MJ. Complex regional pain syndrome as a complication of a chemical burn to the foot. J Burn Care Rehabil 2004;25(2):189-91.
36. van der Laan L, Goris RJA. Reflex sympathetic dystrophy after burn injury. Burns 1996;22(4):303-6.
37. Isakov E, Boduragin N, Korzets A, Susak Z. Reflex sympathetic dystrophy of both patellae following burns. Burns 1995;21(8):616-8.
38. Kim CT, Bryant P. Complex regional pain syndrome (type I) after electrical injury: A case report of treatment with continuous epidural block. Arch Phys Med Rehabil 2001;82(7):993-5.
39. Warner G, Figgitt DP. Pregabalin: As adjunctive treatment of partial seizures. CNS Drugs 2005;19(3):265-72.
40. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews (Online). 2000 (3):CD001415.
41. Van Ameringen M, Mancini C, Pipe B, Bennett M. Antiepileptic drugs in the treatment of anxiety disorders: Role in therapy. Drugs 2004;64(19):2199-220.
42. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry 2003;160(3):533-40.
43. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24(2):141-9.
44. Lauria Horner BA, Pohl RB. Pregabalin: A new anxiolytic. Expert Opin Investig Drugs 2003;12(4):663-72.
45. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23(3):240-9.
46. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004;110:628-38.
47. Backonja M, Beydoun A, Edwards KR, etal. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998;280(21):1831-6.
48. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain 2004;109(1-2):26-35.
49. Dworkin RH, Corbin AE, Young JP Jr, etal. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003;60(8):1274-83.
50. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998;280(21):1837-42.
51. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: A randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 2002;27(5):481-6.
52. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002;18(1):22-7.
53. Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg 2002;95(4):985-91, table of contents.
54. Hill CM, Balkenohl M, Thomas DW, et al. Pregabalin in patients with postoperative dental pain. Eur J Pain 2001;5(2):119-24.
55. Rorarius MG, Mennander S, Suominen P, et al. Gabapentin for the prevention of postoperative pain after vaginal hysterectomy. Pain 2004;110(1-2):175-81.
56. Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg 2005;100(5):1394-9.
57. Field MJ, Oles RJ, Lewis AS, et al. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997;121(8):1513-22.
58. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42(2):229-36.
59. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271(10):5768-76.
60. McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC Pharmacol 2004;4(1):14.
61. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002;303(3):1199-205.
62. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001;21(6):1868-75.